8-K: Microbot Medical Secures $8.6 Million in Registered Direct Offering

Microbot Medical has announced an $8.6 million registered direct offering priced at-the-market, along with a concurrent private placement of preferred investment options.

Summary

• Microbot Medical Inc. has entered into agreements for a registered direct offering of 3,788,550 shares of common stock at $2.27 per share.
• The company is also conducting a concurrent private placement of Series H preferred investment options to purchase up to 7,577,100 shares of common stock at an exercise price of $2.10 per share.
• The preferred investment options are immediately exercisable and expire two years from the issue date.
• The combined offerings are expected to generate gross proceeds of approximately $8.6 million before fees and expenses.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for these offerings.
• The company intends to use the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, as well as for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures funding for the company's operations and development. However, the potential dilution and risks associated with the offering temper the overall sentiment.

Positives

• The capital raise will provide funds for the continued development and commercialization of the LIBERTY Robotic System.
• The company will also be able to expand and develop additional applications from its existing IP portfolio.
• The preferred investment options provide a potential future source of capital if exercised.
• The company has secured a placement agent to assist with the offering.

Negatives

• The offering involves the issuance of new shares, which may dilute existing shareholders.
• The preferred investment options, if exercised, could further dilute existing shareholders.
• The company will incur placement agent fees and other offering expenses, reducing the net proceeds.

Risks

• The closing of the offerings is subject to customary closing conditions, which may not be met.
• The company's ability to obtain additional working capital is not guaranteed.
• There are risks inherent in the development and commercialization of the LIBERTY Endovascular Robotic Surgical System.
• Regulatory approvals, including FDA clearance, are not guaranteed.
• Market conditions and other factors could impact the company's ability to raise future capital.

Future Outlook

The company intends to use the net proceeds from the offerings for the continued development, commercialization and regulatory activities for the Companys LIBERTY Robotic System, expansion and development of additional applications derived from the Companys existing IP portfolio, and for working capital and other general corporate purposes.

Management Comments

• The company has not provided any direct quotes from management in this document.

Industry Context

This announcement reflects a common practice for pre-commercial stage medical technology companies to raise capital for research, development, and commercialization efforts. The use of a registered direct offering and concurrent private placement is a strategy to secure funding while managing dilution and regulatory requirements.

Comparison to Industry Standards

• The use of a registered direct offering and concurrent private placement is a common method for raising capital in the biotech and medical device industries, particularly for companies that are not yet generating significant revenue.
• The terms of the preferred investment options, including the exercise price and expiration date, are within the typical range for such instruments in similar financings.
• The placement agent fee of 7% plus a management fee of 1% is also within the typical range for such services.
• Comparable companies that have used similar financing methods include [list comparable companies if known], which have also raised capital to fund development and commercialization of their products.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees may benefit from the continued development and commercialization of the LIBERTY Robotic System.
• Customers and patients may benefit from the company's products and services in the future.
• Creditors may be impacted by the company's use of proceeds and financial performance.

Next Steps

• The company will close the registered direct offering and concurrent private placement on or about January 9, 2025.
• The company will use the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System.
• The company will file a final prospectus supplement and accompanying prospectus with the SEC.
• The company will apply to list the shares and warrant shares on the Nasdaq Capital Market.

Key Dates

Keywords

registered direct offering, private placement, preferred investment options, common stock, LIBERTY Robotic System, H.C. Wainwright & Co., capital raise, medical technology, dilution, regulatory approvals